185 related articles for article (PubMed ID: 23299909)
1. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.
Hoy J; Grund B; Roediger M; Ensrud KE; Brar I; Colebunders R; Castro ND; Johnson M; Sharma A; Carr A;
J Bone Miner Res; 2013 Jun; 28(6):1264-74. PubMed ID: 23299909
[TBL] [Abstract][Full Text] [Related]
2. Continuous antiretroviral therapy decreases bone mineral density.
Grund B; Peng G; Gibert CL; Hoy JF; Isaksson RL; Shlay JC; Martinez E; Reiss P; Visnegarwala F; Carr AD;
AIDS; 2009 Jul; 23(12):1519-29. PubMed ID: 19531929
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults.
Wattanachanya L; Jantrapakde J; Avihingsanon A; Ramautarsing R; Kerr S; Trachunthong D; Pussadee K; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Phanuphak N; Sunthornyothin S; Phanuphak P;
AIDS Care; 2020 Aug; 32(8):984-993. PubMed ID: 31137948
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Rasmussen TA; Jensen D; Tolstrup M; Nielsen US; Erlandsen EJ; Birn H; Østergaard L; Langdahl BL; Laursen AL
PLoS One; 2012; 7(3):e32445. PubMed ID: 22479327
[TBL] [Abstract][Full Text] [Related]
5. Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.
Seguro LP; Casella CB; Caparbo VF; Oliveira RM; Bonfa A; Bonfa E; Pereira RM
Osteoporos Int; 2015 Feb; 26(2):459-67. PubMed ID: 25146092
[TBL] [Abstract][Full Text] [Related]
6. Decreased serum bone specific alkaline phosphatase and increased urinary N-terminal telopeptide of type I collagen as prognostic markers for bone mineral density loss in HIV patients on cART.
Koga I; Seo K; Yoshino Y; Kitazawa T; Kurahashi I; Ota Y
J Infect Chemother; 2016 Aug; 22(8):543-7. PubMed ID: 27346381
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
Brown TT; Ross AC; Storer N; Labbato D; McComsey GA
Antivir Ther; 2011; 16(7):1063-72. PubMed ID: 22024522
[TBL] [Abstract][Full Text] [Related]
8. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
9. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
10. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
12. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents.
Mora S; Zamproni I; Cafarelli L; Giacomet V; Erba P; Zuccotti G; Viganò A
AIDS; 2007 May; 21(9):1129-35. PubMed ID: 17502723
[TBL] [Abstract][Full Text] [Related]
13. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
[TBL] [Abstract][Full Text] [Related]
17. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
18. Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight.
Viapiana O; Gatti D; Dalle Grave R; Todesco T; Rossini M; Braga V; Idolazzi L; Fracassi E; Adami S
Bone; 2007 Apr; 40(4):1073-7. PubMed ID: 17240212
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy.
Alonso S; Ferrero E; Donat M; Martínez G; Vargas C; Hidalgo M; Moreno E
J Endocrinol Invest; 2012 Jul; 35(7):640-4. PubMed ID: 21946027
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men.
Roshandel D; Holliday KL; Pye SR; Boonen S; Borghs H; Vanderschueren D; Huhtaniemi IT; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC; Thomson W; O'Neill TW;
J Bone Miner Res; 2010 Aug; 25(8):1830-8. PubMed ID: 20205168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
